Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2005 Mar;102(3):230-4.
doi: 10.1007/s00347-004-1150-x.

[Results of the "Ocular hypertension treatment study"]

[Article in German]
Affiliations
Clinical Trial

[Results of the "Ocular hypertension treatment study"]

[Article in German]
N Pfeiffer. Ophthalmologe. 2005 Mar.

Abstract

Ocular hypertension (OHT) is defined as intraocular pressure (IOP) elevated above normal levels which occurs without detectable damage to the papilla or visual field. It is considered to be the most important risk factor for developing primary open-angle glaucoma (POAG). The "Ocular hypertension treatment study" (OHTS) addresses the issue of whether lowering IOC before damage to the papilla or visual field occurs can hinder their development and whether OHT can be treated categorically. This randomized, prospective, nonmasked and non-placebo-controlled, multicenter study documents the protective effect of prophylactic lowering of IOC and identifies and explains the risk factors for developing POAG. These include advancing age, reduced corneal thickness, increased pattern standard deviations in white-on-white perimetry, and elevated vertical or horizontal cup to disc ratio. Due to the large individual differences in risk distribution and the very high costs of treating OHT, the question of whether OHT should be treated on principle remains open in the OHTS. This decision must be made on an individual basis after each patient's risk has been assessed.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Am J Ophthalmol. 2000 Oct;130(4):441-53 - PubMed
    1. Arch Ophthalmol. 2002 Jun;120(6):829-30 - PubMed
    1. Ophthalmology. 1989 Oct;96(10):1460-7 - PubMed
    1. Arch Ophthalmol. 2002 Jun;120(6):714-20; discussion 829-30 - PubMed
    1. Arch Ophthalmol. 1999 May;117(5):573-83 - PubMed

MeSH terms

Substances

LinkOut - more resources